CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 91 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02627924
NCT02627924N/ACompleted

Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab (ROCKA Study)

AbbVie·observational·Posted Dec 11, 2015·Updated Mar 22, 2019

In Brief

An observational study for Rheumatoid Arthritis. Completed, enrolled 91 participants.

Detailed Summary

The study is designed as a prospective, observational study to assess the effect of adalimumab on health-related quality of life (QoL) and work productivity in patients with rheumatoid arthritis (RA) in Korea.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 11, 2015
Enrollment StartNov 18, 2015
Primary CompletionDec 28, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 10.6 years ago